Abstract
Radiation-induced lung fibrosis (RILF) is a severe side effect of radiotherapy in lung cancer patients that presents as a progressive pulmonary injury combined with chronic inflammation and exaggerated organ repair. RILF is a major barrier to improving the cure rate and well-being of lung cancer patients because it limits the radiation dose that is required to effectively kill tumor cells and diminishes normal lung function. Although the exact mechanism is unclear, accumulating evidence suggests that various cells, cytokines and regulatory molecules are involved in the tissue reorganization and immune response modulation that occur in RILF. In this review, we will summarize the general symptoms, diagnostics, and current understanding of the cells and molecular factors that are linked to the signaling networks implicated in RILF. Potential approaches for the treatment of RILF will also be discussed. Elucidating the key molecular mediators that initiate and control the extent of RILF in response to therapeutic radiation may reveal additional targets for RILF treatment to significantly improve the efficacy of radiotherapy for lung cancer patients.
Keywords: Fibrosis, lung cancer, radiotherapy, side effects.
Current Drug Targets
Title:Molecular Mechanisms and Treatment of Radiation-Induced Lung Fibrosis
Volume: 14 Issue: 11
Author(s): Nian-Hua Ding, Jian Jian Li and Lun-Quan Sun
Affiliation:
Keywords: Fibrosis, lung cancer, radiotherapy, side effects.
Abstract: Radiation-induced lung fibrosis (RILF) is a severe side effect of radiotherapy in lung cancer patients that presents as a progressive pulmonary injury combined with chronic inflammation and exaggerated organ repair. RILF is a major barrier to improving the cure rate and well-being of lung cancer patients because it limits the radiation dose that is required to effectively kill tumor cells and diminishes normal lung function. Although the exact mechanism is unclear, accumulating evidence suggests that various cells, cytokines and regulatory molecules are involved in the tissue reorganization and immune response modulation that occur in RILF. In this review, we will summarize the general symptoms, diagnostics, and current understanding of the cells and molecular factors that are linked to the signaling networks implicated in RILF. Potential approaches for the treatment of RILF will also be discussed. Elucidating the key molecular mediators that initiate and control the extent of RILF in response to therapeutic radiation may reveal additional targets for RILF treatment to significantly improve the efficacy of radiotherapy for lung cancer patients.
Export Options
About this article
Cite this article as:
Ding Nian-Hua, Li Jian Jian and Sun Lun-Quan, Molecular Mechanisms and Treatment of Radiation-Induced Lung Fibrosis, Current Drug Targets 2013; 14 (11) . https://dx.doi.org/10.2174/13894501113149990198
DOI https://dx.doi.org/10.2174/13894501113149990198 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Biological Activity of 28-Amide Derivatives of 23-Hydroxy Betulinic Acid as Antitumor Agent Candidates
Medicinal Chemistry Obesity-Driven Inflammation and Colorectal Cancer
Current Medicinal Chemistry Therapeutic Strategy of Erythropoietin in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) FoxQ1 is a Novel Molecular Target for Pancreatic Cancer and is Associated with Poor Prognosis
Current Molecular Medicine Natural Compounds as Antagonists of Canonical Wnt/β-Catenin Signaling
Current Chemical Biology Editorial [Hot Topic: ErbB Family and Downstream Signal Transduction Pathways as Targets for Anticancer Therapy (Guest Editor: F. Caponigro)]
Current Drug Targets Insects Antiviral and Anticancer Peptides: New Leads for the Future?
Protein & Peptide Letters Network-Based Strategies Can Help Mono- and Poly-pharmacology Drug Discovery: A Systems Biology View
Current Pharmaceutical Design Functional Characteristic of Snake Venom Disintegrins: Potential Therapeutic Implication
Current Pharmaceutical Design Complexity in Clinical Trials: Blind Spots, Misleading Criteria, Winners and Losers
Clinical Cancer Drugs Pre-feasibility Study for Establishing Radioisotope and Radiopharmaceutical Production Facilities in Developing Countries
Current Radiopharmaceuticals Meet Our Regional Editor
Clinical Cancer Drugs Cell Culture in Microfluidic Systems
Micro and Nanosystems Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics
Current Drug Delivery Targeting Cancer: The Challenges and Successes of Structure-Based Drug Design Against the Human Purinome
Current Topics in Medicinal Chemistry Recent Progress in the Development of Histone Deacetylase Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Drug-Metabolizing Enzymes Mechanisms and Functions
Current Drug Metabolism Carotenoids as Modulators of Intracellular Signaling Pathways
Current Signal Transduction Therapy